SCHEMBL7682186

SCHEMBL7682186

Cc1cc2cc(C(=O)O)[nH]c2cc1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.63
PIN1 Q13526 1/20 0.62
SMAD3 P84022 1/20 0.55
EIF4A3 P38919 2/20 0.54
KDM4E B2RXH2 2/20 0.53
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.53
SRD5A2 P31213 2/20 0.53
DAO P14920 2/20 0.53
MAPT P10636 1/20 0.53
NFKB1 P19838 2/20 0.53
F7 P08709 1/20 0.53
F3 P13726 1/20 0.53
PDPK1 O15530 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
TSHR P16473 1/20 0.53
APEX1 P27695 1/20 0.53
CYP2C19 P33261 1/20 0.53
TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7040376 0.87 GPR35 (0.73) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL22747199 0.85 GPR35 (0.56) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL7092509 0.85 GPR35 (0.56) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL17429451 0.85 EIF4A3 (0.65) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL765246 0.85 EIF4A3 (0.60) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL3100380 0.83 SRD5A2 (0.58) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL16090785 0.82 MMP2 (0.44) GPR35PIN1EIF4A3KDM4EHPGD
SCHEMBL18332181 0.80 APEX1 (0.51) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL12495305 0.80 PIN1 (0.50) GPR35PIN1SMAD3EIF4A3KDM4E
SCHEMBL31359900 0.80 PIN1 (0.50) GPR35PIN1SMAD3EIF4A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827602-B2 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors Janssen Pharmaceuticals, Inc. (US) 2023-11-28 US disclosed
US-6380230-B1 FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS SANOFI-SYNTHELABO (FR) 2002-04-30 US disclosed
CN-1276790-A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them SANOFI SA (FR) 2000-12-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827602-B2 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors IDO1, IDO2, IRF3 GPR35 2740/4885PIN1 909/4885SMAD3 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.